Table 1. CI values for glioblastoma cultures after combinatorial treatments with ABT263 and JQ1.
| T98G | LN229 | NCH644 | ||||||
|---|---|---|---|---|---|---|---|---|
| ABT263 (μM) | JQ1 (μM) | CI | ABT263 (μM) | JQ1 (μM) | CI | ABT263 (μM) | JQ1 (μM) | CI |
| 0.25 | 5 | 0.01428 | 1.0 | 5 | 0.00373 | 1.0 | 10.0 | 0.02111 |
| 0.5 | 4.0 | 0.02653 | 0.5 | 2.5 | 0.00186 | 2.0 | 8.0 | 0.01897 |
| 1.0 | 3.0 | 0.02098 | 0.25 | 1.0 | 0.00679 | 3.0 | 5.0 | 0.00564 |
| 2.0 | 2.0 | 0.00294 | 0.125 | 0.5 | 0.09112 | 4.0 | 3.0 | 0.02502 |
| 2.0 | 5.0 | 0.00911 | 0.125 | 5.0 | 0.45551 | 4.0 | 10.0 | 0.01669 |
| 1.0 | 4.0 | 0.01894 | 0.25 | 2.5 | 0.03430 | 3.0 | 8.0 | 0.00758 |
| 0.5 | 3.0 | 0.03524 | 0.5 | 1.0 | 0.06114 | 2.0 | 5.0 | 0.01316 |
| 0.25 | 2.0 | 0.02639 | 1.0 | 0.5 | 0.12614 | 1.0 | 3.0 | 0.01122 |
ABT263 treatment elicits a synergistic anti-proliferative effect on LN229, T98G glioma cells and NCH644 stem cell-like glioma cells in the presence of the c-myc inhibitor, JQ1. The CompuSyn software (ComboSyn, Inc., Paramus, NJ) was used for the drug-drug interaction analysis including the calculation of the combination index (CI). A CI<1 was considered as synergistic, a CI=1 as additive and a CI>1 as antagonistic.